Title : Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer - the role of STAT3 and p21.

Pub. Date : 2020 Aug

PMID : 31375978






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer - the role of STAT3 and p21. ibrutinib erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 Ibrutinib is a recently approved Tyrosine Kinase Inhibitor (TKI) that has been shown be an effective therapeutic option for HER2 overexpressing breast cancer. ibrutinib erb-b2 receptor tyrosine kinase 2 Homo sapiens
3 The molecular mechanisms, pathways, or genes that are modulated by ibrutinib and the mechanism of action of ibrutinib in HER2 overexpressing breast cancer remain obscure. ibrutinib erb-b2 receptor tyrosine kinase 2 Homo sapiens
4 In this study, we have performed a kinome array analysis of ibrutinib treatment in two HER2 overexpressing breast cancer cell lines. ibrutinib erb-b2 receptor tyrosine kinase 2 Homo sapiens
5 These results suggest that inhibitors of STAT3 phosphorylation may be potential options for combination therapy to help increase the efficacy of ibrutinib against HER2-overexpressing tumors. ibrutinib erb-b2 receptor tyrosine kinase 2 Homo sapiens